Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toho Pharm.: Sales Up 9.5%, Operating Profits Up 52.9%
June 4, 2007
- Korosho Proposes Switching to Generics to Lift Price Agreement Rate
June 4, 2007
- VITAL-NET: Aiming at Ordinary Profits-to-Sales Ratio of 2.2%
June 4, 2007
- Otsuka: Sales Up 18.5% to \576.1 Bil. Driven by Strong Overseas Sales
June 4, 2007
- Yakult Honsha: Elplat Drives Sales with 78.1% Growth in Sales
June 4, 2007
- BUSINESS NEWS IN BRIEF
June 4, 2007
- OPINION／Would You Follow Someone Like You?
June 4, 2007
- NEJM Article on Avandia "Based on Incomplete Evidence": GSK
June 4, 2007
- R&D NEWS IN BRIEF
June 4, 2007
- REGULATORY NEWS IN BRIEF
June 4, 2007
- Korosho Has No Plan to Cut Initial/Repeat Consultation Fees: Korosho Officials
June 4, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 4, 2007
- Generics and Original Drugs Are Not the Same: Prof. Uchida
June 4, 2007
- SELF-MEDICATION NEWS IN BRIEF
June 4, 2007
- GENERIC NEWS IN BRIEF
June 4, 2007
- MEDICAL DEVICE NEWS IN BRIEF
June 4, 2007
- Mediceo Paltac: Sales Exceed \2 Tril. Mark
June 4, 2007
- SURVEY／Low Expectations for Treatment of ADHD in Japan: Eli Lilly
June 4, 2007
- Alfresa HD: Sales Up 12.6% to \1,590 Bil., Big Jump in Profits
June 4, 2007
- New JGPMA President H. Sawai Aims at 30% Share for Generics
June 4, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…